Navigation Links
Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility
Date:1/18/2011

.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.  Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  CONTACT: Amgen, Thousand OaksMary Klem, 805-447-6979 (media) Arvind Sood, 805-447-1060 (investors)Contact:  Boehringer IngelheimU.S. Media Inquiries:Jason Kurtz, Communications & PR440-201-3668Jason.Kurtz@boehringer-ingelheim.comOutside the U.S.:Heidrun Thoma, Corporate Communications, Germany49/6132 77 3966Heidrun.Thoma@boehringer-ingelheim.comMedia + PR Boehringer Ingelheim GmbH55216 Ingelheim/GermanyE-mail: '/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
2. Boehringer Ingelheim Initiates Phase III Clinical Trial With Afatinib in Advanced Breast Cancer
3. Boehringer Ingelheims Pradaxa Available in U.S. Pharmacies Starting Wednesday, November 3
4. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
5. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
6. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
7. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
10. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
11. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Inferior Vena Cava (IVC) Filters - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... to reach US$435 million by 2016. The ... of the global value while Europe ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... ultra rapid acting insulin presented at the American Diabetes ... ORLEANS, June 6 /PRNewswire-FirstCall/ -- ... investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA ... to standard of care therapies in controlling post-meal blood ...
... June 6 Boehringer Ingelheim Pharmaceuticals, Inc. today announced ... the type 2 diabetes therapeutic area. The Company ... clinical development worldwide. New Phase II data results ... inhibitor and the Company,s lead diabetes compound, were presented ...
Cached Medicine Technology:Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 2Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 3Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4Boehringer Ingelheim Unveils Diabetes Pipeline 2Boehringer Ingelheim Unveils Diabetes Pipeline 3Boehringer Ingelheim Unveils Diabetes Pipeline 4Boehringer Ingelheim Unveils Diabetes Pipeline 5
(Date:12/17/2014)... Project Veritas is releasing a video interview of ... and Obamacare architect Jonathan Gruber to public attention. Award-winning ... which is being distributed on YouTube. , During the ... the Affordable Care Act in order to hide a ... per year tax grab. , “President Obama promised us ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Greater participation ... new study finds. Researchers followed kids in the ... to poor children in Los Angeles. Over two ... larger improvements in how the brain processes speech and ... Also, the benefits of active participation in music ...
(Date:12/15/2014)... Cancer researchers have just published an important new ... malignant pleural mesothelioma. Surviving Mesothelioma has just posted an ... here to read it now. , Doctors at ... New York’s Langone Medical Center performed complete genetic analyses ... an effort to pinpoint the genes that are most ...
(Date:12/15/2014)... December 15, 2014 OutMarket , ... released “ Social Media Cheat Sheets ,” a guide ... that drives results on the top ten social media ... It helps drive awareness, engagement, and customer service. It ... to make an impact on new networks and weather ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Kathy McAfee, ... prestigious Women World Awards in the category of Best ... gold award for her weekly career blog Networking ... advice to help professionals elevate their talent and influence ... blog, named after her book Networking Ahead for Business, ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... at about 15 months of age to prevent heart disease ... bmj.com today. , High cholesterol which runs ... two in every 1000 people and causes very high levels ... blood. It carries a high risk of death from coronary ...
... expand options, reduce costs for ECC training, ... Heart,Association research has supported education and training programs ... lives each year.,Now, healthcare providers have more ways ... as the organization introduces a,significantly expanded eLearning program. ...
... Hospital Group to Automate and Connect 165 ... Physicians Across 36 Medical Groups, ... the leading provider of clinical software, connectivity and,information solutions that ... Health System (WPAHS) has selected,Allscripts as its Electronic Health Record ...
... to Make a Blood Donation to Honor Blood ... Collectors and Support Their Communities, LAKE ... of September 16-22, 2007, blood collection centers across the,United States ... and Fenwal, Inc. This celebratory week recognizes the important,service blood ...
... requires lifelong dependence on insulin injections, researchers say , ... insulin-linked gene can cause permanent neonatal diabetes, say American ... mutations in 21 people from 16 families. , Permanent ... affects infants and leads to lifelong dependence on insulin ...
... Saturday,September 15 will mark the first national "Short ... advocacy group, will be holding special,events in several ... City and,Washington, DC, musicians with psoriasis will headline ... have a,cookout; and across the country, people with ...
Cached Medicine News:Health News:Experts propose cholesterol tests at 15 months of age 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 2Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 3Health News:American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC) 4Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 2Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 3Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 4Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 2Health News:AABB and Fenwal Sponsor Third Annual Blood Collectors Week 3Health News:Gene Mutations May Cause Rare Neonatal Diabetes 2Health News:Psoriasis Cure Now Rolls Out First National 'Short Sleeve Day' Saturday 2
Custom Conjugation Services...
Colloidal Gold Conjugated, Streptavidin - 50 OD...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD...
Medicine Products: